STATE STREET CORP - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 126 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.61 and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$17,459,000
+12.8%
5,135,293
+24.8%
0.00%0.0%
Q2 2018$15,471,000
-26.2%
4,114,687
-19.8%
0.00%
-50.0%
Q1 2018$20,975,000
-22.2%
5,128,223
-11.6%
0.00%0.0%
Q4 2017$26,977,000
+5.4%
5,801,219
+60.9%
0.00%0.0%
Q3 2017$25,598,000
+13.2%
3,605,496
+15.3%
0.00%0.0%
Q2 2017$22,611,000
+5.5%
3,127,848
-10.1%
0.00%0.0%
Q1 2017$21,432,000
+26.3%
3,479,370
+20.1%
0.00%0.0%
Q4 2016$16,973,000
-10.2%
2,896,746
-18.7%
0.00%0.0%
Q3 2016$18,908,000
+14.0%
3,561,785
+42.1%
0.00%0.0%
Q2 2016$16,588,000
+22.1%
2,506,192
-13.8%
0.00%
+100.0%
Q1 2016$13,581,000
-32.4%
2,907,401
-26.9%
0.00%
-50.0%
Q4 2015$20,100,000
-16.6%
3,979,791
-41.9%
0.00%
-33.3%
Q3 2015$24,108,000
-43.2%
6,847,735
+61.1%
0.00%
-40.0%
Q2 2015$42,412,000
+2.8%
4,249,614
+31.1%
0.01%
+25.0%
Q1 2015$41,254,000
+9.9%
3,240,983
+22.1%
0.00%0.0%
Q4 2014$37,549,000
+1.5%
2,653,395
-1.4%
0.00%0.0%
Q3 2014$37,009,000
-8.5%
2,691,371
+2.3%
0.00%0.0%
Q2 2014$40,469,000
-15.9%
2,631,452
-6.8%
0.00%
-20.0%
Q1 2014$48,134,000
+24.1%
2,824,904
-28.3%
0.01%
+150.0%
Q4 2013$38,775,000
+5.8%
3,942,205
+8.6%
0.00%
-60.0%
Q3 2013$36,651,000
+28.9%
3,629,045
-4.7%
0.01%
+25.0%
Q2 2013$28,436,0003,806,7900.00%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q2 2017
NameSharesValueWeighting ↓
VHCP Management, LLC 700,273$10,770,0005.76%
HARVEY CAPITAL MANAGEMENT INC 932,400$14,340,0005.13%
Camber Capital Management LP 3,000,000$46,140,0003.02%
Baupost Group 10,539,986$162,105,0002.64%
SECTORAL ASSET MANAGEMENT INC 3,741,656$57,547,0002.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,884,409$59,742,0002.40%
Knoll Capital Management, LLC 200,000$3,076,0001.37%
DAFNA Capital Management LLC 92,400$1,421,0001.35%
NORTHPOINTE CAPITAL LLC 892,011$13,719,0001.32%
Rhenman & Partners Asset Management AB 240,000$3,691,0001.10%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders